SDF-1 and CXCR4 in synovium are associated with disease activity and bone and joint destruction in patients with rheumatoid arthritis treated with golimumab.

Abstract

OBJECTIVES:

The aim of this study was to determine whether the levels of stromal cell-derived factor (SDF)-1 and its receptor C-X-C chemokine receptor 4 (CXCR4) in synovium were correlated with clinical outcome and bone and joint destruction in rheumatoid arthritis (RA) patients being treated with golimumab.

METHODS:

Synovial tissues were obtained from 15 golimumab-treated patients and were assessed for SDF-1 and CXCR4 using a new immunohistological scoring system (IH score). The IH score was used to assess correlations between synovial SDF-1 or CXCR4 and the disease activity score (DAS28 CRP), Rooney score, tumor necrosis factor alpha, interleukin-6 (IL-6), CD4, CD20, CD68 and the Assessment of RA by Scoring of Large-Joint Destruction and Healing in Radiographic Imaging (ARASHI) score. Receiver-operating characteristic (ROC) curves were used to predict ARASHI scores from the CXCR4 IH scores.

RESULTS:

SDF-1 strongly correlated with the DAS28 CRP and serum IL-6. CXCR4 correlated with synovial CD4 and the ARASHI score. ROC analysis of CXCR4 and ARASHI scores >10 indicated a cutoff of 12 points on the IH score for predicting joint destruction during treatment.

CONCLUSIONS:

Synovial SDF-1 correlated with disease activity, and its receptor CXCR4 was related to joint destruction in RA patients treated with golimumab.

• Authors: Katsuaki Kanbe, Junji Chiba, Yasuo Inoue, Masashi Taguchi, Akiko Yabuki
• Journal: Modern rheumatology (Mod Rheumatol) Vol. 26 Issue 1 Pg. 46-50 ( 2016) ISSN: 1439-7609 [Electronic] England
• PMID: 25995033 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• CXCL12 protein, human
• CXCR4 protein, human
• Chemokine CXCL12
• IL6 protein, human
• Interleukin-6
• Receptors, CXCR4
• Tumor Necrosis Factor-alpha
• golimumab

Topics

• Adult
• Aged
• Aged, 80 and over
• Antibodies, Monoclonal (therapeutic use)
• Arthritis, Rheumatoid (drug therapy, metabolism, pathology)
• Bone and Bones (pathology)
• Chemokine CXCL12 (metabolism)
• Female
• Humans
• Interleukin-6
• Male
• Middle Aged
• Receptors, CXCR4 (metabolism)
• Severity of Illness Index
• Synovial Membrane (metabolism, pathology)
• Tumor Necrosis Factor-alpha